doi:10.1016/j.ymgme.2006.02.007
Copyright © 2006 Elsevier Inc. All rights reserved.
Subacute combined degeneration of the spinal cord in cblC disorder despite treatment with B12
Sharon E. Smitha, c, Hannah C. Kinneyb, d, Kathryn J. Swobodae and Harvey L. Levya, c,
, 
aDivision of Genetics, Children’s Hospital Boston, MA 02115, USA
bDepartment of Pathology (Neuropathology), Children’s Hospital Boston, MA 02115, USA
cDepartment of Pediatrics, Harvard Medical School, USA
dDepartment of Pathology, Harvard Medical School, USA
eDepartment of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
Received 22 November 2005;
revised 13 February 2006;
accepted 14 February 2006.
Available online 30 March 2006.
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Abstract
Subacute combined degeneration (SCD) of the spinal cord is a characteristic complication of vitamin B12 deficiency, but it has never been neuropathologically demonstrated in a B12-inborn error of metabolism. In this report SCD is documented in a 15-year-old boy with early-onset cobalamin C (cblC) disorder. The neuropathologic findings included multifocal demyelination and vacuolation with predilection for the dorsal and lateral columns at the mid-thoracic level of the spinal cord, confirming the similarity of SCD in cblC disorder to the classic adult SCD due to vitamin B12 deficiency. SCD developed in this boy despite treatment for cblC disorder that began at 3 months of age. There is clinical and experimental evidence to suggest that a deficiency in remethylation with concomitant reduction in brain methionine may be the cause of SCD. In this patient plasma methionine levels were low without betaine and/or l-methionine supplementation and in the normal range for only a 2-year period during compliance with therapy. In cblC disorder, a consistent increase in blood methionine to high normal or above normal levels by the use of betaine and l-methionine supplementation may be helpful in preventing SCD. This is especially important now that the presymptomatic detection of cblC disorder is possible through the expansion of newborn screening.
Keywords: Cobalamin; cblC disorder; Subacute combined degeneration; Peripheral neuropathy; Neuropathology; Myelopathy; Demyelination; Methionine; Remethylation; Inborn errors of metabolism; Methylmalonic acid; Homocysteine; Homocystinuria; Methylmalonic acidemia
Fig. 1. Methyl transfer pathway showing the transfer of a methyl group to homocysteine via B12 for the methylation of homocysteine to form methionine; the alternative remethylation to methionine using a methyl group from betaine; and the contribution of a methyl group from S-adenosylmethionine (SAM) for many transmethylations. THF is tetrahydrofolate; B12 is cobalamin; DMG is dimethylglycine. Enzymes involved are italicized.
Fig. 2. Plasma methionine levels by age and treatment strategy. *Denotes possibly the first clinical signs of myelopathy; **denotes the first clinical signs of a peripheral neuropathy; ***denotes the EMG and MRI findings suggestive of demyelination. The normal range is indicated between the dotted lines.
Fig. 3. Posterior column of the spinal cord. (A) A low power view of the posterior column (fasciculis cuneatus) adjacent to the dorsal horn (DH) of the thoracic spinal cord demonstrates with foci of demyelination and vacuolation, reactive astrocytes, and macrophages. 20×. Hematoxylin-and-eosin/Luxol-fast-blue. (B) Large vacuoles due to myelin sheath splitting (arrows) are seen at high magnification 40×. Hematoxylin-and-eosin/Luxol-fast-blue.
Fig. 4. Frontal Lobe. (A) At low power, there are scattered foci of demyelination (arrows) in the central white matter of the posterior frontal lobe. Hematoxylin-and-eosin/Luxol-fast-blue. ×4. (B) The foci of demyelination are characterized by myelin degeneration, reactive astrocytes (arrow heads), macrophages with myelin debris in their cytoplasm (arrows), and a rare axonal spheroid (asterisk). Hematoxylin-and-eosin/Luxol-fast-blue, ×40.